Keith Regnante insider trades: Keros Therapeutics (KROS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Keith reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | KROS | ↓ Sell | 4,739 | $16.35 | $77K | Direct | Feb 20, 2026 (2d) |
| Nov 4, 2023 | KROS | ↓ Sell | 40,000 | $45.29 | $1.8M | Direct | Jan 8, 2024 (65d) |
| Jun 9, 2023 | KROS | ↓ Sell | 40,000 | $46.61 | $1.9M | Direct | Jun 12, 2023 (3d) |
| Feb 19, 2019 | WVE | ↓ Sell | 1,298 | $36.84 | $48K | Direct | Feb 21, 2019 (2d) |
| Sep 24, 2018 | WVE | ↓ Sell | 29,500 | $55.00 | $1.6M | Direct | Sep 26, 2018 (2d) |
| Feb 16, 2018 | WVE | ↓ Sell | 316 | $51.85 | $16K | Direct | Feb 21, 2018 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KROS insiders
Open-market trades in the last 12 months
About Keith Regnante's insider trades
Keith Regnante is Chief Financial Officer at Keros Therapeutics (KROS). Since Feb 16, 2018, Keith has reported no open-market purchases and 6 sales worth $5.4M on SEC Form 4. In the last 12 months: 1 sale ($77K).
Their filings also include grants and awards (10 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KROS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.